CA
NZ
UK
AU
IND
US
Harvard Bioscience reported anEarnings Per Share(EPS) of $-0.14, surpassing analyst expectations by 33% against a $-0.21 consensus estimate. This performance indicates strengthening fundamentals in a challenging market, potentially appealing to investors looking for growth opportunities.Key HighlightsHarvard Bioscience (NASDAQ: HBIO) reported an earnings per share …
Kardigan, Inc. recorded a net loss of $116.2 million for the second quarter, increasing from a loss of $57.4 million year-over-year. The robust cash position of $661 million ensures ample funding for ongoing clinical trials, making it crucial for investors monitoring the company's future …
Strongest Revenue Performance in Q1 2027
Mereo BioPharma Group plc has finalized an agreement that couldYield$40 million in upfront payments and up to $435 million in milestone payments for the rights to alvelestat, a treatment for AATD-LD. This vitalPartnershipmarks an essential step towards capitalizing on a new market opportunity, enhancing …
Sagimet Biosciences reported an EPS of $-0.33 for the second quarter, surpassing the $-0.38 consensus estimate. This outperformance amid a 62.6% year-to-date stock increase signals potential growth for investors in the biopharmaceutical sector.Key HighlightsStock up 62.6% year-to-date, reflecting strong market interest.Insiders sold $578,900 worth …
Earnings Performance Exceeds Consensus
Cantor Fitzgerald Reaffirms BridgeBio's Overweight Rating
Following the announcement on August 4, shares rose 3.1% to $244.60 in pre-market trading. Over the past year, the stock has shown notable resilience, with a 52-week price range between $137.75 and $244.87. This increase speaks to a healthy market sentiment around the company's …
Immediate FDA Approval for CLiK™ Extra
Canopy Growth's Stock Plummets Over 99%
Please wait processing your request...